Efficacy of the Standard Treatment and Fusion Ontogenetic Surgery for Gynecologic Cancers

Launched by SEOUL NATIONAL UNIVERSITY HOSPITAL · Dec 6, 2016

Keywords

ClinConnect Summary

This clinical trial is looking at two different ways to treat gynecologic cancers, specifically cervical and uterine cancer. Researchers want to see how effective the standard treatment compares to a new procedure called fusion ontogenetic surgery, which involves advanced surgical techniques designed to remove cancer more completely. The study will also examine how these treatments affect patients' health, any side effects they might cause, and how long patients live after treatment.

To participate in this trial, women aged 20 and older who have certain types of cervical or uterine cancer may be eligible. This includes those with early-stage or more advanced cancer who haven’t had much success with other treatments. Participants will need to be in relatively good health and must agree to join the study by signing an informed consent form. Those who take part can expect to receive either the standard treatment or the new surgical approach, and they will be closely monitored throughout the trial. It’s important to note that this study is currently recruiting participants, so there is an opportunity for eligible women to contribute to this important research.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Female, Age ≥ 20 years
• • Patients with primary, recurrent, or refractory cervical cancer (FIGO stage IB1-IVA), primary, recurrent, or refractory uterine cancer (FIGO stage IA, grade 3, IB-IVA), or gynecologic cancer patients showing pelvic sidewall recurrence.
• • ECOG performance status 0 or 1
• • Extensive surgery might be expected to cure the disease, or expected to relieve severe pelvic pain.
• • Patients who signed an approved informed consent
• • Patients who do not have a treatment option other than surgery.
• Exclusion Criteria:
• • Female, Age \< 20 years
• • ECOG performance status ≥2
• • Bilateral pelvic sidewall invasion
• • Patients who had undergone radical hysterectomy, trachelectomy, or hysterectomy in case of the primary disease.
• • Patients who refused to sign an informed consent